References
- Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, , German Hodgkin's Lymphoma Study Group, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386–2395
- Cutuli B, Borel C, Dhermain F, Magrini S M, Wasserman T H, Bogart J A, et al. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol 2001; 59: 247–255
- Stein H, Foss H D, Dürkop H, Marafioti T, Delsol G, Pulford K, et al. CD30 anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96: 3681–3695
- Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family which is characteristic for Hodgkin's disease. Cell 1992; 68: 421–427
- Schwarting R, Gerdes J, Dürkop H, Falini B, Pileri S, Stein H. Ber-H2: a new anti Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989; 74: 1678–1689
- Schnell R, Borchmann P, Schulz H, Engert A. Current strategies of antibody-based treatment in Hodgkin's disease. Ann Oncol 2002; 13(Suppl 1)57–66
- Baluna R, Ghetie V, Oppenheimer-Marks N, Vitetta E S. Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells. Int J Immunopharmacol 1996; 18: 355–361
- Youle R J, D'Alessio G. Antitumor RNases. Ribonucleases: Structures and Functions, G D'Alessio, J F Riordan. Academic Press, New York 1997; 491–511
- Saxena S K, Rybak S M, Winkler G, Meade H M, McGray P, Youle R J, et al. Comparison of RNases and toxins upon injection into Xenopus oocytes. J Biol Chem 1991; 266: 21208–21214
- Psarras K, Ueda M, Tanabe M, Kitajima M, Aiso S, Komatsu S, et al. Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNase1-human-IL-2 fusion. Cytokine 2000; 12: 786–790
- Huhn M, Sasse S, Tur M K, Matthey B, Schinköthe T, Rybak S M, et al. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001; 61: 8737–8742
- Stöcker M, Tur M K, Sasse S, Krüßmann A, Barth S, Engert A. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif 2003; 28: 211–219
- Zewe M, Rybak S M, Dübel S, Coy J F, Welschof M, Newton D L, et al. Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology 1997; 3: 127–136
- Drexler H G. The Leukemia-Lymphoma Cell Line Facts Book. Academic Press, San Diego 2001
- Nanni P, de Giovanni C, Lollini P L, Nicoletti G, Prodi G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983; 1: 373–380
- Schneider I. Cell lines derived from late embryonic stages of Drosophila melanogaster. J Embryol Exp Morphol 1972; 27: 363–365
- Huston J S, Levinson D, Medgett-Hunter M, Tai M S, Novotny J, Margolies M N, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 5879–5883
- Dübel S, Breitling F, Klewinghaus I, Little M. Regulated secretion and purification of recombinant antibodies in E. coli. Cell Biophys 1992; 21: 69–79
- Coligan J E, Kruisbeek A M, Margulies D H, Shevach E M, Stroiber W. Current Protocols in Immunolgy. John Wiley, New York 2006
- Kreitman R J, Wilson W H, White J D, Stetler-Stevenson M, Jaffe E S, Giardina S, et al. Phase I trial of recombinant immunotoxin antiTac(Fv)-PE3 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622–1636
- Hofsteenge J. Ribonuclease inhibitor. Ribonucleases: Structures and Functions, G D'Alessio, J F Riordan. Academic Press, New York 1997; 621–658
- Murthy B S, Sirdeshmukh R. Sensitivity of monomeric and dimeric forms of bovine seminal ribonuclease to human placental ribonuclease inhibitor. Biochem J 1992; 281: 343–348
- Gaur D, Swaminathan S, Batra J K. Interaction of human pancreatic ribonuclease with human ribonuclease inhibitor. J Biol Chem 2001; 276: 24978–24984
- Matousek J. Ribonucleases and their antitumor activity. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 2001; 129: 175–191
- Futami J, Maeda T, Kitazoe M, Nukui E, Tada H, Seno M, et al. Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups. Biochemistry 2001; 40: 7518–7524